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A novel method for the measurement of plasma
metanephrines using online solid phase extraction-liquid
chromatography tandem mass spectrometry
Joanne E Adaway1,2, Mirko Peitzsch3 and Brian G Keevil1,2
Abstract
Background: Measurement of plasma metanephrine, normetanephrine and 3-methoxytyramine is useful in the diag-
nosis of phaeochromocytomas, but many assays require a large volume of plasma due to poor assay sensitivity, and often
require lengthy sample preparation. Our aim was to develop a method for measurement of plasma metanephrines using a
small sample volume with minimal hands-on preparation.
Methods: Samples were deproteinised using 10K spin filters prior to online solid phase extraction using a Waters
Acquity UPLC Online SPE Manager (Waters, Manchester, UK) coupled to a Waters Xevo TQ-S mass spectrometer
(Waters, Manchester, UK). The assay was validated and results compared to a previously published method.
Results: We achieved a limit of quantification of 37.5 pmol/L for metanephrine and 3-methoxytyramine and 75 pmol/L
for normetanephrine using only 150 mL of sample. The assay was linear up to 30,000 pmol/L for all analytes and in a
method comparison study results showed good agreement with a previously published LC-MS/MS assay.
Conclusions: We have developed a simple method for measurement of plasma metanephrine, normetanephrine and
3-methoxytyramine using only 150mL of sample. There is minimal hands-on sample preparation required and the assay is
suitable for routine use in a clinical laboratory.
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Introduction
Phaeochromocytomas and paragangliomas (PPGLs)
are rare tumours of adrenal chromaffin cells or similar
tissue in extra-adrenal paraganglia. Biochemical
diagnosis of these tumours is important due to the
non-specific nature of symptoms such as hypertension,
palpitations, flushing and sweating. Analysis of plasma
metanephrines is used as a first line test for the diagno-
sis of adrenal and extra-adrenal sympathetic PPGLs.1
Plasma metanephrines are produced from catechol-
amines within chromaffin cells by the action of
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catechol-O-methyl transferase (COMT). Adrenaline is
metabolized to metanephrine (MN), noradrenaline to
normetanephrine (NMN) and dopamine to 3-methox-
ytyramine (3MT). Many of the current plasma meta-
nephrine assays only measure MN and NMN, but there
is evidence that measurement of 3MT gives important
information on tumour location, the presence of under-
lying mutations of SDHB and SDHD genes and the
likelihood of metastases,2 with 3MT shown to be
higher in patients with metastases compared to those
without. It is advantageous to offer 3MT measurement
as part of plasma metanephrine analysis, but this can be
challenging due to the low picomolar concentrations
found in the majority of samples.
Current methods for the measurement of plasma
metanephrines include immunoassay,3,4 HPLC with
electrochemical detection5 and liquid chromatography
tandem mass spectrometry (LC-MS/MS).6–10
Immunoassays do not offer the option of 3MT analysis,
and HPLC with electrochemical detection suffers from
interferences from common substances such as para-
cetamol,11 so LC-MS/MS is increasingly the method
of choice for metanephrine analysis.
LC-MS/MS analysis of analytes in complex matrices
such as plasma often requires extensive sample prepar-
ation. Solid phase extraction is the most common
sample preparation method for plasma metanephrines,
with both oﬄine7–10 and online6 methods reported in
the literature; however, 3MT was not measured in two
of these assays,7,9 and some required high sample vol-
umes for analysis.6,7
We wanted to develop an online solid phase extrac-
tion (SPE)method for the measurement of plasmameta-
nephrines to decrease the hands-on preparation time for
use in a busy clinical laboratory. TheWaters Online SPE
Manager (OSM), (Waters, Manchester, UK) is an
online separation device designed for use with the very
high back pressure encountered when running UPLC
conditions. In particular, the extraction cartridges
have been manufactured with thicker walls, to ensure
a liquid tight junction under the higher pressures, but
this reduces the amount of chromatographic packing
material available for use. As a result of this fundamen-
tal design change, the preconditioning, washing and elu-
tion parameters of the OSM are uniquely different from
those reported for similar systems designed for use
under HPLC conditions.6 We often receive low
volume samples for plasma metanephrine analysis and
wished to develop a method with minimal sample
volume requirements with sufficient sensitivity to allow
the quantification of MN, NMN and 3MT. We felt that
the OSM combined with a highly sensitive mass spec-
trometer would allow us to develop such a method.
In this report, we describe the development and val-
idation of a semi-automated online SPE-LC-MS/MS
method for the measurement of MN, NMN and 3MT
using only 150 mL of plasma.
Materials and methods
Calibrator and reagent preparation
Stock solutions were prepared by dissolving 10mg of
3-methoxytyramine powder (Sigma-Aldrich, Poole,
UK) in 0.1mol/L hydrochloric acid. Catecholamine
mix 2, consisting of 1mg/mL of MN and NMN in
methanol was used as the stock for MN and NMN
(LGC standards, Middlesex, UK). Separate stocks
were used for standards and quality control samples
(QCs). The stocks were then diluted in phosphate buf-
fered saline pH 7.4 (PBS; Sigma-Aldrich, Poole, UK)
containing 0.1% (w/v) bovine serum albumin (BSA;
Sigma, Poole, UK), to give standard concentrations of
0–30,000 pmol/L for MN and 3MT and 0–32,300 pmol/
L for NMN and QC concentrations of 200, 1000 and
3000 pmol/L for MN and 3MT and 220, 1090 and
3270 pmol/L for NMN. Aliquots (200 mL) of these
were stored at 80C for up to six months. A mixed
internal standard of deuterated d3-metanephrine (a-d2
b-d1), d3-normetanephrine (a-d1, b-d2) and d4-3-meth-
oxytyramine (a-d2, b-d2) (Medical Isotopes, New
Hampshire, USA) was used as the internal standard at
a working concentration of 2000 pmol/L in water. This
was found to be stable at 4C for six months.
Sample preparation
Standards, QCs and patients’ samples (150mL) were
pipetted directly into a 10K modified PES centrifugal
filter (VWR, Leicestershire, UK). To this, 150mL of
working internal standard was added and the filter vor-
texed for 10 s. The filter was then centrifuged at 9962 g
for 20min, and the filtrate transferred into a well of a
96-deep well block (Porvair Sciences, Wrexham, UK).
The block was heat sealed (Thermo, Hemel Hempstead,
UK), and then centrifuged at 8000 g for 5min.
Online solid phase extraction and liquid
chromatography
The plate was transferred into a Waters Acquity UPLC
system coupled to an Online SPE manager (OSM)
(Waters, Manchester, UK). The OSM is under full soft-
ware control and allows preconditioning, loading,
washing and elution of the SPE cartridges. An Oasis
weak cation exchange (WCX) 1 10mm and 30 mm
SPE cartridge (Waters, Manchester, UK) were placed
in the right clamp and preconditioned twice with
200 mL of acetonitrile containing 2% (v/v) formic
acid, followed by 250 mL of 80% acetonitrile: 20%
362 Annals of Clinical Biochemistry 52(3)
10mmol/L ammonium formate pH 3.2 in water fol-
lowed by 250 mL of 95% acetonitrile. The cartridge
was then equilibrated with 250mL water, and 100 mL
of sample was loaded onto the cartridge via the
Acquity autosampler with 250 mL of water. Unbound
contaminants were removed by washing the cartridge
with 200 mL of water followed by 200 mL of 95% aceto-
nitrile. The cartridge was then automatically trans-
ferred to the left hand clamp for elution of the
analytes from the cartridge directly onto the analytical
column under the initial chromatographic conditions.
The analytical column was an Atlantis Hilic Silica
2.1 50mm, 3 mm column (Waters, Manchester, UK),
coupled to a SecurityGuard Gemini C18 4 2mm
guard cartridge (Phenomenex, Macclesfield, UK).
Whilst eluting the sample in the left clamp, the next
sample is prepared in the right clamp, thus improving
throughput.
Mobile phase A contained 100mmol/L ammonium
formate in deionized water adjusted to pH 3.2 with
formic acid, and mobile phase B contained acetonitrile.
Initial conditions were 5:95 (v/v) A:B. Metanephrines
were eluted from the column using a gradient of 5–20%
mobile phase A over 4.1min. These conditions were
held for 0.3min before returning to initial conditions
for a further 2.74min to re-equilibrate the column. The
flow rate was 0.3mL/minute throughout and the total
run time was 7.15min.
Mass spectrometry
The eluate was injected from the OSM directly into a
Xevo TQ-S tandem mass spectrometer (Waters,
Manchester, UK). MassLynx software was used for
system control and the MassLynx TargetLynx pro-
gramme allowed data processing. The software used
the height of the detected peaks, 1/ weighting and
linear least squares regression to produce a standard
curve. The mass spectrometer was operated in electro-
spray positive ionization mode, the capilliary was main-
tained at 0.5 kV and the source temperature was 150C.
The desolvation gas flow and temperature were 800L/h
and 650C, respectively. The transitions and collision
energies for the analytes are given in Table 1. The cone
voltage was 40V for all analytes with a source offset of
30V. Transitions were monitored in multiple reaction
monitoring (MRM) mode with a dwell time of 0.15 s.
Assay validation
Ion suppression
To investigate ion suppression, we infused a 2 nmol/L
solution of d3-MN, d3-NMN and d4-3MT in water
directly into the mass spectrometer via the Waters
IntellistartTM Fluidics system to give a constant back-
ground signal. Plasma samples (n¼ 6) were prepared as
detailed earlier and injected simultaneously via the
autosampler. Ion suppression is seen as a reduction in
background signal, and this is significant if it occurs
where the compound of interest elutes, and although
there is no official guidance on acceptable concentra-
tions of ion suppression, for the purpose of this study
we decided that a reduction in signal of less than 10%
would be acceptable. In addition, plasma samples
(n¼ 5) were doubly diluted with PBS/0.1% (v/v) BSA
up to a 1:32 dilution to assess the linearity of the dilu-
tions, as the compounds of interest would dilute non-
linearly in the presence of ion suppression.
Lower limit of quantification
The lower limit of quantification (LLOQ) was in
accordance with FDA Guidance.12 Fifteen replicates
of low, medium and high concentrations of MN,
NMN and 3MT in PBS/0.1% BSA were analysed and
the LLOQ was determined as the lowest concentration
of each with % coefficient of variation (CV) <20 and
accuracy within 20% of expected concentrations.
Imprecision and accuracy
To determine the intra-assay imprecision of the assay,
the three QC samples were prepared and analysed 10
times within one batch. To determine the inter-assay
imprecision, the three samples were analysed 15 times
in different batches. The imprecision was deemed
acceptable if the CV was <15%, and the accuracy
was deemed acceptable if the mean value was within
15% of the weighed in value.
Linearity
The linearity of the method was evaluated by
analysing calibrators containing MN and 3MT up to
a concentration of 30,000 pmol/L and NMN up to
Table 1. MRM Transitions and collision energies for each
analyte.
Analyte
Precursor
ion (m/z)
Product
ion (m/z)
Collision
energy (eV)
MN 180 148.1 17
d3-MN 183.1 151.1 15
NMN 166.0 134.1 15
d3-NMN 169.0 137.1 17
3MT 151.0 119.05 12
d4-3MT 155.0 123.1 14
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32,300 pmol/L. Calibration curves (n¼ 10) were pro-
duced using TargetLynx software, which plotted cali-
brator concentration values against the corresponding
Online SPE-LC-MS/MS response (analyte peak height/
stable isotope labelled analyte peak height). The assay
was determined to be linear if the 1/ linear regression
analysis produced an r2 >0.99.
Recovery
Three different concentrations of the three analytes
(500, 1000 and 3000 pmol/L) were spiked onto six dif-
ferent plasma samples. Total recovery was calculated
from measured compared to expected concentra-
tions, and was deemed to be acceptable if between
80 and 120%. Extraction recovery was determined
using the Advanced Method Development (AMD)
feature in the MassLynx software. Briefly, two cart-
ridges were placed in series, and a sample and washes
were applied to the first cartridge. Any sample lost from
the first cartridge (breakthrough analyte) was captured
on the second cartridge. The second cartridge was
then eluted, followed by the first, and the amount of
analyte eluted was quantified using TargetLynx
software. Extraction recovery was calculated as the
peak height of the analyte recovered from cartridge 1
divided by the peak height of breakthrough analyte
plus the peak height of the analyte eluted from cart-
ridge 1.
Method comparison
Plasma samples (n¼ 206) were analysed by online SPE-
LC-MS/MS and by LC-MS/MS with oﬄine SPE.10 All
samples used were part of the prospective monoamine-
producing tumor study (https://pmt-study.pressor.org)
and were taken after an overnight fast and with the
patient in the fully supine position for 30min before
blood sampling. Samples were initially analysed by off-
line SPE within one month of collection. They were
then stored at 80C for a mean of 1.68 years, prior
to shipping frozen in dry ice and storage for a max-
imum of 2 weeks before analysis by online SPE.
Samples have been shown to be stable under these con-
ditions.13 All subjects provided informed consent under
protocols approved by the local Ethics committees at
each participating centre.
Diagnostic sensitivity and specificity
Receiver Operating Characteristic (ROC) analysis was
carried out on 206 plasma samples to ascertain the
diagnostic sensitivity and specificity of both online
and oﬄine SPE assays. Of the samples, 36 were from
patients with confirmed PPGLs and 170 were
from patients in whom PPGL had been excluded as a
diagnosis.
Drug interference
It has previously been shown that isoproterenol and
MDMA interfere with normetanephrine quantification,
and isoetharine and MDA interfere with metanephr-
ine.14 To investigate this, compounds were spiked into
water plus two plasma pools at concentrations at least
three times the upper limit of the appropriate reference
limit (isoproterenol 47 mmol/L, MDMA 5.2mmol/L,
isoetharine 42 mmol/L and MDA 5.6 mmol/L). The con-
centrations of metanephrine, normetanephrine and
3MT were calculated and compared to those in the
pools spiked with an equivalent volume of water.
Statistical analysis
All statistical analyses were carried out using Analyse-it
software (Analyse-it software Ltd, Leeds, UK) apart
from ROC analysis which was done using the JMP
Pro 10.0 software package (SAS, Cary, NC, USA).
Results
SPE and liquid chromatography
Chromatographic separation of 3MT, MN and NMN
was achieved within 4min (Figure 1) with a further
3min required to wash and re-equilibrate the column,
giving a total run time of 7.15min. Each analyte
co-eluted with the stable isotope labelled version.
Ion suppression
There was no significant suppression of the background
signal at the time of analyte elution for any of the three
analytes. Ion enhancement occurs after 5min, but this
does not interfere with analyte quantification. We fur-
ther investigated ion suppression by serially diluting
patients’ samples in PBS/0.1% (v/v) BSA. The analy-
te:internal standard peak ratio was used to calculate the
concentration of each dilution from a standard curve,
and these concentrations were plotted against
the expected values. Dilution linearity of five patients’
samples showed an r2 value >0.99 for all three analytes,
indicating that ion suppression does not affect this
assay.
Lower limit of quantification
The lower limit of quantification for MN was
37.5 pmol/L, with a CV of 7% and a bias of þ5.9%.
The LLOQ for NMN and 3MT was 75 pmol/L, with
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CVs of 5.8 and 5.4% and deviation from the target
value of 3.4 and þ8.4%, respectively.
Imprecision
The intra- and inter-assay imprecision and bias was
acceptable at low, medium and high concentrations
for all three analytes, with CV and deviation from the
target value below 10% for all analytes at all three con-
centrations (Table 2).
Linearity
Standard curves were produced by plotting the analyte
concentration on the x-axis and the response (analyte
peak height/internal standard peak height) on the
y-axis. The curve was linear up to 30,000 pmol/L for
MN and 3MT and up to 32,300 pmol/L for NMN,
with r2 values greater than 0.99 over multiple batches.
A representative slope for MN was 0.9997 (SE 0.0002)
with an intercept of 2.4604 (SE 2.0274), and the SE of
the residuals was 4.1438. For NMN, a representative
slope was 0.9971 with an intercept of 21.91 (SE 0.0014
and 19.09, respectively), and SE of the residuals was
39.03. A typical 3MT standard curve had a slope of
1.0053 (SE 0.0030) with an intercept of 36.95 (SE
38.88), and the SE of the residuals was 79.47.
Recovery
The mean total recovery of MN, NMN and 3MT was
98% (87–108%), 97% (86–107%) and 95% (80–109%),
respectively, which were all within acceptable limits.
The extraction recovery was 92% for MN, 94% for
Figure 1. Chromatogram of a plasma sample containing 149 pmol/L metanephrine, 345 pmol/L normetanephrine and 110 pmol/L
3-methoxytyramine. The internal standards d3-metanephrine, d3-normetanephrine and d4-3MTare also shown on the chromatogram.
Table 2. Intra- and inter-assay imprecision and deviation from
target values.
Analyte/
concentration
(pmol/L)
Intra-assay
CV (%)
Deviation
from
target (%)
Inter-assay
CV (%)
Deviation
from
target
Metanephrine
200 9.5 8.3 9.3 3.5
1000 6.2 6.5 4.7 7.0
3000 3.7 5.3 3.3 6.3
Normetanephrine
220 7.9 3.6 2.2 3.4
1090 4.1 0.1 1.6 2.6
3270 3.3 2.4 1.6 4.3
3-Methoxytyramine
200 8.7 8.5 2.9 3.8
1000 3.7 1.8 2.5 5.9
3000 2.1 0.6 2.0 2.1
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NMN and 97% for 3MT, indicating that losses from
the cartridge are minimal.
Method comparison
MN, NMN and 3MT were measured in 206 samples by
online SPE-LC-MS/MS and by a previously published
LC-MS/MS method10 with oﬄine solid phase extrac-
tion. Sixteen of the 206 samples were below the LLOQ
of our assay for MN and were excluded from the com-
parison. Bland-Altman analysis showed the online SPE
method had a mean negative bias of 23% over a range
of 37.5 pmol/L to >12000 pmol/L (Figure 2(a)). All the
NMN results were within the measuring range, and
Bland-Altman analysis showed a mean positive bias
of 0.1% (Figure 2(b)). The NMN results ranged from
113 pmol/L to greater than 40,000 pmol/L. Of the 206
samples, 163 were below the measuring range of 3MT
in our assay, leaving 43 for inclusion in the comparison,
with the highest 3MT concentration >22,000 pmol/L.
A mean negative bias of 12.4% was shown in the
Bland-Altman analysis (Figure 2(c)).
Diagnostic sensitivity and specificity
The diagnostic sensitivity and specificity was calculated
for each assay using the cut-offs used in each laboratory
(Table 3). The reference ranges used for online SPE
were based on the work of Peaston et al.8 with
<510 pmol/L for MN, <1180 pmol/L for NMN and
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Figure 2. Comparison between offline and online SPE methods for metanephrine, normetanephrine and 3-methoxytyramine. Panel
(a) shows Bland-Altman analysis for metanephrine samples, and panels (b) and (c) show Bland-Altman analysis for normetanephrine
and 3-methoxytyramine, respectively. The solid line represents the mean percentage difference between the two methods; dotted
lines represent the confidence limits which are 1.96% SD.
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<180 pmol/L for 3MT. The reference ranges for the
oﬄine SPE method were 446 pmol/L for MN and
179 pmol/L for 3MT.10 Age-adjusted reference ranges
were used for NMN, as described by Eisenhofer et al.15
ranging from 590 pmol/L for a 5-year-old to 1037 pmol/
L for patients 60 years old and above. Using these cut-
offs, the sensitivity of the online assay was 94.4%,
whilst the oﬄine assay had a sensitivity of 100%. The
specificity of the two assays was similar at 96.5% for
online SPE and 95.8% for oﬄine SPE (Table 3). ROC
analysis confirms the good diagnostic sensitivity and
specificity of both assays, with an area under the
curve (AUC) of 0.995 for oﬄine SPE and 0.979 for
online SPE (Figure 3).
Drug interference
None of the drugs tested showed peaks in water at the
retention times of MN, NMN or 3MT. In addition, the
drugs did not affect the concentration of any of the
three analytes in the plasma pools, indicating that inter-
ference from these drugs is negligible in this assay.
Discussion
We have developed a method for the measurement of
MN, NMN and 3MT in plasma that is suitable for
routine clinical use. The combination of centrifugal fil-
ters and online SPE for sample preparation is novel and
require minimal hands-on preparation time, which is
important in a busy clinical laboratory. The filtration
is required in this assay as the OSM is coupled to an
Acquity UPLC system, and the viscosity of plasma pre-
pared without filtration would be too high for the
narrow bore tubing of the UPLC system and would
quickly cause blockages. We tried other methods to
remove proteins such as acetonitrile precipitation and
trichlorocacetic acid precipitation, but found that we
did not get reproducible results using these techniques.
We found that the recovery obtained from deproteinis-
ing the samples using the centrifugal filters was accept-
able and consistent and therefore decided to validate
the method using this sample preparation.
It has recently been reported that MN may cause
ionic cross-talk in LC-MS/MS assays leading to
overestimation of 3MT.16 This is not a problem with
this assay as the resolution between 3MT and MN is
sufficient that cross-talk does not interfere in the quan-
tification of 3MT (Figure 1).
The lower limits of quantification for MN, NMN
and 3MT allow quantification of samples within pub-
lished reference ranges,8 and the linearity of the assay
up to 30,000 pmol/L for MN and 3MT and
32,300 pmol/L for NMN allows quantification of the
majority of raised samples. If we obtain a result
higher than this, the dilution linearity experiment
proved that it is valid to dilute the sample with PBS/
0.1% (v/v) BSA to produce a concentration within the
measuring range of the assay that can then be multi-
plied back up.
A method comparison against a published oﬄine
SPE LC-MS/MS method10 was carried out using sam-
ples taken from patients who were enrolled in the pro-
spective monoamine producing tumour study. The
comparison between the two methods was acceptable,
with a small negative bias observed with the online-SPE
method for MN and 3MT and a small positive bias for
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Figure 3. Receiver Operating Characteristic (ROC) curve
analysis for offline SPE and online SPE. The sensitivity and
specificity of each assay are plotted for different cut-off points.
The area under the curve is shown for each method.
Table 3. Diagnostic sensitivity and specificity of online and offline SPE methods.
True
positive
True
negative
False
positive
False
negative
Diagnostic
sensitivity (%)
Diagnostic
specificity (%)
Online SPE 34 164 6 2 94.4 96.5
Offline SPE 36 163 7 0 100 95.8
Note: The sensitivity and specificity were calculated using the cut-offs currently in use in the two laboratories.
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NMN, and the diagnostic sensitivity and specificity for
both the assays were shown to be very good. The lar-
gest differences were in very high results; this would not
affect the diagnosis of any patient and may be due to
calibration differences between the two assays. The
samples were taken from patients after an overnight
fast who had been in the supine position for 30min.
We currently use reference ranges derived from the
work of Peaston et al.8 which were based on samples
taken from patients in the sitting position. This refer-
ence range was used as we carried out a comparison of
our previous plasma metanephrine assay against the
Peaston method, and our previous method compared
well with our current method, with a mean bias of
3.2% for metanephrine and 4.1% for normeta-
nephrine. It has been established that supine rest
prior to blood sampling gives significantly lower results
for the metanephrines compared to samples taken in
the sitting position,17,18 and the difference between the
cut-offs used may explain the false negative results with
our method. Using the age-adjusted reference ranges
for NMN and the supine cut-offs for MN and
3MT,15 the sensitivity of our assay does improve to
97.2% (35 true positive, one false negative) in this
supine, fasted population. This is at the expense of spe-
cificity, which falls to 91.3% (11 false positives, 115 true
negatives); however, it may be argued that as plasma
metanephrine analysis is used as a screening test for
PPGL, the importance of not missing the diagnosis is
such that the sensitivity should be maximized.
This work was carried out using samples that had
been collected with ideal pre-venepuncture patient
preparation, i.e. patient fully supine for 30min.
However, we are aware that the vast majority of sam-
ples that we receive are taken from patients in the sit-
ting position and that the facilities for supine blood
sampling may not be readily available in phlebotomy
clinics. In such patients, therefore, the use of a fasting,
supine reference range would significantly decrease the
specificity of this test. Asking for a repeat sample col-
lected under ideal conditions would increase the speci-
ficity, but as Da¨rr et al.18 suggest that there is a problem
with this approach, as for a variety of reasons the
majority of such patients do not get repeat metanephr-
ine analysis undertaken. Da¨rr et al.18 also suggest that
if supine samples cannot be taken, urine fractionated
metanephrines should be used as an alternative test.
However, the accurate collection of timed urine sam-
ples may also pose difficulties and we therefore suggest
that the use of a ‘sitting position’ reference range for
plasma metanephrines may represent a pragmatic alter-
native approach.
In conclusion, we have developed a method for
plasma metanephrine analysis that is suitable for use
in the clinical laboratory using a minimal amount of
sample. We plan to carry out further work on appro-
priate cut-offs for our population to maximize the diag-
nostic sensitivity and specificity of the test in our
routine patients’ samples.
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